Follow us for updates
© 2022 reportr.world
Read the Story →

Philippines to Get Cheaper Version of Merck COVID Pill

A total of 105 middle to low-income nations will get it.
by Agence France Presse
Jan 21, 2022
Photo/s: Merck
Shares

GENEVA -- Generic drug manufacturers will make a more affordable version of Merck's anti-COVID pill for 105 of the world's poorer nations, including the Philippines, in deals announced Thursday by a UN-backed organization.

The global Medicines Patent Pool signed agreements with 27 manufacturers to produce the oral antiviral medicine molnupiravir, for supply in low- and-middle-income countries.

"This is a critical step toward ensuring global access to an urgently needed COVID-19 treatment and we are confident that... the anticipated treatments will be rapidly available in LMICs," said MPP executive director Charles Gore.

Merck granted a license to the MPP in an agreement announced in October. The MPP, in turn, issued sub-licenses to the generic drugs makers, in agreements announced Thursday.

The sub-licenses allow manufacturers to produce the raw ingredients for molnupiravir, and/or the finished drug itself.

The companies involved are spread across Bangladesh, China, Egypt, Jordan, India, Indonesia, Kenya, Pakistan, South Africa, South Korea and Vietnam.

Continue reading below ↓

Five manufacturers will focus on producing the raw ingredients; 13 will produce both raw ingredients and molnupiravir itself; while nine will simply produce the finished drug.

ALSO READ:

Merck's COVID Pill Hailed After Cutting Hospitalizations by Half

FDA Approves First Anti-COVID Pill in Philippines for Emergency Use

Reduction in deaths

In December, the U.S. Food and Drug Administration regulator authorized molnupiravir for high-risk adults, a day after giving the go-ahead to a similar but more effective drug made by Pfizer.

Antivirals like molnupiravir and Pfizer's Paxlovid pill work by decreasing the ability of a virus to replicate, thereby slowing down the disease.

Merck's pill is taken within five days of symptom onset and was shown in a trial of 1,400 participants to reduce COVID-19 hospitalizations and deaths by 30% among at-risk people.

Pfizer's pill reduced the same outcomes by almost 90%.

Merck, also called MSD outside the United States, jointly developed molnupiravir with the Miami-based company Ridgeback Biotherapeutics.

Continue reading below ↓
Recommended Videos

"Accelerating broad, affordable access to molnupiravir has been a priority for MSD from the start," said MSD's director for policy and government relations, Paul Schaper.

"We are pleased to see this vision come to life."

Sales royalties waived

Molnupiravir's creators will not receive sales royalties while COVID-19 remains classified as a public health emergency of international concern (PHEIC) by the World Health Organization.

A PHEIC is the highest alarm the WHO can sound and its emergency committee last week reconfirmed the pandemic's top-alert status.

After the PHEIC ends, the royalties will be 5% of net sales for public sector purchases, and 10% of net sales for commercial entities.

The 105 countries covered include some of the world's most heavily populated nations like India, Indonesia, Pakistan, Nigeria, Bangladesh, Ethiopia, the Philippines, and Egypt.

The Geneva-based MPP is a United Nations-backed international organization that works to facilitate the development of medicines for low- and middle-income nations.

Continue reading below ↓

While the search for vaccines has resulted in multiple products being approved for emergency use in the pandemic, the hunt for treatments for those who have already caught the disease has not been as fruitful.

Until now, the main treatments have been synthetic antibodies or Gilead's antiviral remdesivir, which are administered by infusion.

Pills are easier to make than vaccines, do not require a cold chain for delivery, and can be self-administered by the patient.

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
Human rights lawyer Neri Colmenares made the announcement.
Sinopharm recipients are now eligible to get boosters, too.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to reportr.world newsletter, you agree to our Terms of Service and Privacy Policy.